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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterised by progressing aseptic, symmetric polyarthri-
tis, which causes erosive changes and ankylosis of joints.
Prolonged and aggressive course of the disease may also
cause internal injuries. RA is the most common inflamma-
tory arthritis in adults. It is known that around 0.5–1% of
adults worldwide suffer from this disease. Due to various
reasons, RA frequently is diagnosed too late, when irrepara-
ble changes in joints and outside joints have already oc-
curred, making the use of effective therapy more difficult.
As the disease progresses in a patient, gross joint deforma-
tions develop, which significantly restrict work and self-
care ability. Over time, inflammation may affect almost any
joint. There are drugs that act on different mechanisms in
pathogenesis of the disease, providing more effective con-
trol of the disease course and preventing its progression. Al-
though RA is not completely curable and its treatment is
life-long, it is possible to achieve disease remission. Every
patient may have different progress of the disease — from
mild, slowly progressing arthritis with periodic remissions
to aggressive, quickly progressing and very active arthritis
with early development of deformations.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes erosive changes and
ankylosis of joints and may cause internal injuries. Osteoarthritis (OA) is a degenerative process
of the articular cartilage. However, inflammatory mediators may play a pivotal role in the initiation
and perpetuation of the OA process. It is necessary to continue to study possible factors that may
promote the development of the disease. The goal of this study was to evaluate the frequency
and activity stage of parvovirus B19 (B19V) and persistent human herpes virus (HHV)-6 and
HHV-7 infection in RA and OA patients, and healthy persons, in relation to cytokine levels and
presence or absence of viral infections. RA patients with active B19V infection had the highest
levels of tumour necrosis factor alpha (TNF-), which may contribute to the development of RA.
In the case of OA, the TNF- level was higher in patients with active persistent B19V infection,
suggesting that B19V reactivation affects also OA. Interleukin (IL)-6, IL-10 and metalloproteinase
(MMP)-9 levels were higher in RA patients with latent HHV-6/-7 infection in comparison with ac-
tive HHV-6/-7 infection, whereas in OA patients levels of all studied cytokines were very variable,
ranging from low to high but without significant differences. This suggests that also latent HHV-6
and -7 viral infections can promote development of RA.
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Osteoarthritis (OA) is a degenerative arthritis characterised
by severe cartilage degeneration and secondary inflamma-
tion. The development of OA can be fostered by various
factors. A distinction is made between primary OA, the de-
velopment of which is primarily influenced by hereditary
factors, and secondary OA, which develops as a result of
other diseases or conditions. The development of secondary
OA is facilitated by: various metabolic diseases; traumatic
joint damage; anatomical reasons; any inflammatory arthri-
tis and septic arthritis. A persistent infection, such as latent
herpesvirus or chronic bacterial infection, can contribute to
the development of OA inflammation (Firestein, 2009a).
RA is an autoimmune disease, which is based on immune
system disorders. RA develops in genetically predisposed
individuals affected by a range of different external and in-
ternal factors. Awareness of these factors can facilitate the
treatment of RA. Smoking, large consumption of caffeine,
cold injury and psycho-emotional or physical stress, as well
as different infectious agents, including both bacteria and
viruses, are external factors that can promote the disease.
The most well-studied viral agents are parvovirus B19
(B19V), rubella virus, human herpes viruses (HHVs) and
others. B19V (Parvoviridae family, Parvovirinae subfam-
ily, Erythrovirus genus) is a non-enveloped single-stranded
DNA virus found worldwide. Productive B19V infection is
restricted to erythroid progenitor cells and its clinical pre-
sentation in patients may vary. The most common clinical
syndromes of B19V are erythema infectiosum, polyarthritis,
transient aplastic crisis and pure red cell aplasia, as well as
hydrops fetalis, while skin lesion, hepatitis, neurological
diseases, changes in blood cell composition, as well as rheu-
matic diseases, including RA, are less common. B19V in-
creases levels of inflammatory cytokines (Feldmann et al.,
1996; Kerr et al., 2001; Isa et al., 2006), it activates CD4+
T lymphocytes (Struyk et al., 1994, von Poblotzki et al.,
1996; Isa et al., 2006), and participates in the formation of
immune complexes (Ahrem et al., 1997; Lehmann et al.,
2002). In addition, B19V stimulates production of cyclo-
oxygenase-2 (COX-2), secretion of matrix metalloprotein-
ase-9 (MMP-9) and prostaglandin E2 in synoviocytes and
induces invasiveness of synoviocytes and the degradation of
cartilage by activated synoviocytes (Ray et al., 2001; Lu et
al., 2006).
HHV-6 and -7 (Herpesviridae family, Beta-herpesvirinae
subfamily, and Roseolovirus genus) are double-stranded
DNA viruses. They are frequently found in persons with
neuro-inflammatory diseases. The first infection usually oc-
curs in childhood. As the virus does not become fully elimi-
nated, it creates a persistent life-long infection. An injury,
physical and emotional stress, hormonal disbalance or im-
mune suppression may contribute to reactivation of the in-
fection. HHV-6A, HHV-6B, and HHV-7 have profound in-
fluence on cytokine production by various immune cells.
HHV-6 has been demonstrated to upregulate the production
of interleukin (IL) -1 and tumour necrosis factor alpha
(TNF-) by PBMCs (Flamand et al., 1991; Gosselin et al.,
1992).
The correlation between B19V, HHV-6 and -7 and the de-
velopment of RA has been studied for a long time, however,
the published data are ambiguous and often contradictory.
The goal of the study was to assess the role of viral infec-
tion in RA and OA comparing the frequency of the B19V
infection activity stage, as well as HHV-6 and HHV-7 reac-
tivation in patients and healthy persons.
MATERIALS AND METHODS
Patients and controls. The prospective study included pa-
tients in the Rîga East Clinical University Hospital, and the
Hospital of Traumatology and Orthopaedics in the period
from 2010 to 2016. Inclusion criteria were primary or re-
motely diagnosed RA or OA. All RA patients met the RA
classification criteria set by the American College of Rheu-
matology in 1987 (Arnett et al., 1988) or early RA classifi-
cation criteria set by the American College of Rheumatol-
ogy and the European League Against Rheumatism in 2010
(Aletaha et al., 2010). The exclusion criteria were other in-
flammatory diseases. OA patients corresponded to the OA
classification criteria set by the American College of Rheu-
matology (Altman et al., 1986; 1990., Altman et al., 1991).
Potentially healthy individuals without known chronic in-
flammatory diseases were included in the study as a control
group.
One hundred and three Caucasian RA patients were in-
cluded in the study: 13 men (12.9%) and 90 women
(87.1%), with average age 56.3 ± 12.8 (ranging from 19 to
82). The number of men among RA patients was signifi-
cantly less than in the OA patient group (p = 0.001; OR 0.3,
95% CI: 0.1 to 0.6) and in the group of healthy control indi-
viduals (p = 0.0047; OR 0.3, 95% CI: 0.1 to 0.6). RA pa-
tients were significantly older compared to healthy individ-
uals (p = 0.0047; OR 4.6, 95% CI: 0.1 to 9.1). The average
duration of the disease in this group was 93.7 (0–576)
months.
The RA patient group included 37 patients with early RA
with the duration of symptoms 24 months or less (Emery,
1994) and 66 remotely diagnosed patients.
Since inflammation plays a certain role in OA development
and course, causing subhondral bone and cartilage damage
(Berenbaum, 2013), OA patients also were included in this
study as a second group. Seventy-eight OA patients were
examined in the study: 26 Caucasian men (33%) and 52
Caucasian women (67%), with average age 64.6 ± 12.0
(ranging from 35 to 86). OA patients were significantly
older than RA patients (p < 0.0001; OR 8.3, 95% CI: 4.6 to
11.9) and healthy control individuals (p < 0.0001; OR 12.9,
95% CI: 8.4 to 17.4). The average duration of the disease in
the group was 78.6 (2–300) months.
Forty-three potentially healthy Caucasian control group in-
dividuals without known chronic inflammatory diseases
were included in the study. This group included 15 men
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(34.9%) and 28 women (65.1%), with average age 51.7 ±
11.9 (ranging from 38 to 89).
The Ethics Committee of the Rîga Stradiòð University had
approved the study protocol and all individuals signed an
informed consent form before their inclusion in the study.
Sample collection and preparation. All clinical laboratory
indicators were determined in the respective clinics in local
laboratories. EDTA anti-coagulated peripheral blood sam-
ples from RA, OA and apparently healthy persons were col-
lected. Plasma was separated from peripheral blood by cen-
trifugation.
DNA was isolated from whole blood and cell-free blood
plasma by standard phenol-chloroform extraction. Before
DNA extraction plasma samples were treated with DNase I.
To assure the quality of the whole blood DNA and to ex-
clude contamination of plasma DNA by cellular DNA de-
bris a beta-globin PCR was carried out.
Determination of persistent B19 infection and its stage
of activity. The presence of B19V genomic sequences was
determined using nested PCR (nPCR) as described previ-
ously (Barah et al., 2001). Presence of the B19V genomic
sequence in DNA isolated from cell-free plasma was used
as a marker of active infection (viremia), while presence of
the B19V genomic sequence in DNA isolated from whole
blood was used as a marker of latent persistent infection.
The viral load was determined using real-time PCR technol-
ogy with a TaqMan probe for VP-1 gene, according to the
manufacturer’s protocol (Roboscreen, Germany).
Determination of B19 specific antibodies. B19V specific
IgM class and IgG class antibodies were determined using
the ELISA recomWell kit (Microgen, Germany), based on
the manufacturer’s recommendations. The plasma presence
of B19V antibodies to certain B19V antigens was re-
confirmed using the recomLine Parvovirus IgM and IgG
test (Microgen, Germany) guided by the manufacturer’s
recommendations.
Determination of persistent HHV-6 and HHV-7 infec-
tion and its stage of activity. One microgram of whole
blood DNA as well as 10 µl of plasma DNA were subjected
to nPCR with HHV-6 and HHV-7 specific primers as de-
scribed previously (Secchiero et al., 1995; Berneman et al.,
1992, respectively). Detection of viral DNA in whole blood
was used as a marker of persistent infection while detection
of viral DNA in cell-free blood plasma as a marker of active
infection (virus reactivation). Number of persons with latent
infection was calculated as the difference between numbers
of patients with persistent and active infection.
Determination of the cytokine level. Levels of MMP-9
and cytokines TNF-, IL-6, and IL-10 were determined us-
ing enzyme-linked immunosorbent assay (ELISA) kits from
Nordic Biosite, Denmark (TNF-, IL-6), R&D system,
USA (MMP-9), and Affymetrix eBioscience, USA (IL-10).
ELISA’s were performed and the results analysed according
to manufacturer’s instructions.
Statistical analysis. The quantification limit (QL) for assay
of cytokines assessment was set as 1 pg/ml. Cytokine lev-
els below QL were uniformly set as values around QL/2
(Beal, 2001; Rogers et al., 2018), i.e., in the range of
0.3–0.6 pg/ml. Mean levels of all clinical, laboratory pa-
rameters and plasma cytokines and MMP-9 were expressed
as medians with variability characterised by the interquartile
region (IQR). The distributions of cytokine levels were
mostly lognormal and, therefore, are summarized also in
natural units as geometric means. Statistical differences in
the detection frequency of B19V, HHV-6, and HHV-7 ge-
nomic sequences in the extracted DNA samples of the indi-
viduals with RA and OA as well as the control group per-
sons were assessed with the Fisher’s exact test and T-test.
Significant differences between the groups was assessed by
a quantitative approach applying the nonparametric Mann
Whitney U test or Kruskal–Wallis test with uncorrected
Dunn’s test as a post-hoc procedure, as well as by a qualita-
tive approach using the Chi-square test to compare propor-
tions of measurements (< 1/> 1). Statistical significance was
set at p < 0.05.
All analyses and graphing were performed using Prism 8.01
for macOS software (Graph Pad, San Diego, CA, USA).
RESULTS
Presence of B19V infection markers according to re-
comWell, recomLine and PCR test. RA patients. Tests
were performed for 96 RA patients. Based on recomWell
and PCR results, the RA patients were divided into five
groups: (1) 37 RA patients with remote B19V infection
(presence of B19V IgG class antibodies only), (2) 15 RA
patients with acute B19V infection (presence of B19V IgM
class antibodies and/or viremia), (3) 14 RA patients with
B19V latent persistent infection (presence of B19 IgG class
antibodies and B19V genomic sequences in blood DNA),
(4) 19 RA patients with B19V active persistent infection
(presence of B19V IgG class antibodies and viremia) and
(5) 11 RA without B19V infection (without B19V specific
antibodies and virus-specific DNA).
OA patients. Testing was carried out for 78 OA patients.
Based on recomWell and PCR results, OA patients were di-
vided into five groups: (1) 44 OA patients with remote
B19V infection (presence of B19 IgG class antibodies), (2)
9 OA patients with active persistent B19V infection (pres-
ence of B19V IgG class antibodies and viremia), (3) 9 OA
patients with latent persistent B19V infection (presence of
B19 IgG class antibodies and B19V genomic sequences in
blood DNA), (4) 5 OA patients with acute B19V infection
(presence of B19V IgM class antibodies and/or viremia)
and (5) 11 OA patients without B19V infection.
Antibodies to 4–5 different B19V antigens were found in
59.8% of OA patients. IgG class antibodies against B19V
NS-1 were found in 22.1% of OA patients. In the groups of
OA patients with different activity stages of B19V infec-
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tion, a viral genomic sequence was more commonly found
in the case of latent persistent B19V infection (p = 0.045).
Healthy individuals. Testing was carried out for 19 control
group individuals. Based on recomWell and PCR results
evaluation 12 control group individuals were with remote
B19V infection, one — with active persistent B19V infec-
tion, one — with latent persistent B19V infection, one —
with acute B19V infection and four — without B19V in-
fection.
In plasma of healthy control group individuals, virus-
specific antibodies against no more than four different
B19V antigens were found.
Cytokine and MMP-9 levels of RA, OA patients and
healthy individuals with different activity stages of
B19V infection. RA patients. The MMP-9 level in RA pa-
tients with active persistent B19V infection was found to be
significantly lower than in RA patients with remote B19V
infection (p = 0.006, Fig. 1). The TNF- level in the group
of RA patients with remote B19V infection was lower than
in the group of RA patients with active persistent B19V in-
fection (p = 0.05) and with acute B19V infection (p = 0.05).
However, in the group of RA patients with acute B19V in-
fection, the TNF- level was lower compared to the patients
with latent persistent B19V infection (p < 0.05) and with
active persistent B19V infection (p < 0.05, Fig. 2). The IL-6
level was lower in RA patients with active persistent B19V
infection than in patients without B19V infection (p < 0.01),
with remote B19V infection (p < 0.01) and in the RA pa-
tients with acute B19V infection (p < 0.05, Fig. 3). The
IL-10 level was lower in RA patients without B19V infec-
tion than in patients with acute B19V infection (p < 0.01),
and lower in RA patients with active persistent B19 infec-
tion than in patients with remote B19V infection (p < 0.05,
Fig. 4).
OA patients. A lower MMP-9 level was observed in the
group of OA patients with active persistent B19V infection
compared to the group without B19V infection (p < 0.01)
and with remote B19V infection (p < 0.05, Fig. 1). A higher
TNF- level was found in OA patients with active persis-
tent B19V infection compared to OA patients with latent
persistent B19V infection (p = 0.01), remote B19V infec-
tion (p = 0.01) and without B19V infection (p = 0.01). Also,
in the OA patients with acute B19V infection, the TNF-
level was higher than in patients with remote B19V infec-
tion (p = 0.05, Fig. 2). The level of IL-6 was lower in OA
patients with acute B19V infection than in patients without
B19V infection (p < 0.05, Fig. 3). The level of IL-10 in the
groups of OA patients did not differ significantly depending
on the activity stage of B19V infection.
Healthy individuals. No significant difference in levels of
MMP-9 and cytokines was found among control group indi-
viduals with different activity stages of B19V infection.
No significant difference in MMP-9 and cytokine levels
was found between healthy control group individuals with
remote B19V infection and RA patients with remote B19V
infection.
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Fig. 1. Level of MMP-9 in RA (A, C) and OA (B, D) patients with various B19V (A, B) and HHV-6 and HHV-7 (C, D) infection activity stages; bars repre-
sent geometric mean with geometric SD, gray dotted line connects medians with IQR (bold gray lines), *p < 0.05, **p < 0.01, ****p < 0.0001.
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Fig. 2. Level of TNF- in RA (A, C) and OA (B, D) patients with various B19V (A, B) and HHV-6 and HHV-7 (C, D) infection activity stages; bars repre-
sent geometric mean with geometric SD, gray dotted line connects medians with IQR (bold gray lines), *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 3. Level of IL-6 in RA (A, C) and OA (B, D) patients with different B19V (A, B) and HHV-6 and HHV-7 (C, D) infection activity stages; bars represent
geometric mean with geometric SD, gray dotted line connects medians with IQR (bold gray lines), *p < 0.05, **p < 0.01.
No significant differences in MMP-9 and cytokine levels
were found between the OA patient group and the healthy
control group individuals, in the case when both had remote
B19V infection.
HHV-6 and HHV-7 infection markers. RA patients. Per-
sistent HHV-6 and/or persistent HHV-7 infection was found
in 67/80 (81.3%) RA patients. Of these cases, 6/67 (9.0%)
had single HHV-6 infection, 42/67 (62.7%) — single
HHV-7 infection and 19/67 (28.4%) — concurrent HHV-6
and -7 infection. Reactivation of single HHV-6 was found
in 10/67 (14.9%) cases with persistent infection, and reacti-
vation of HHV-7 — in 11/61 (18.0%) cases with persistent
HHV-7 infection. Two of 19 RA patients with persistent
concurrent HHV-6 and HHV-7 infection demonstrated reac-
tivation of both HHV-6 and HHV-7 viruses (10.5%).
Among RA patients persistent HHV-6 mono-infection at la-
tent stage was found in 4/6 (66.7%) patients. Persistent
HHV-7 infection at latent stage was found in 31/42 (73.8%)
and concurrent persistent HHV-6 and HHV-7 infection at
latent stage in 11/19 (57.9%) RA patients.
OA patients. Persistent HHV-6 and/or persistent HHV-7 in-
fection was found in 63/78 (80.8%) OA patients. Among
these 63 OA patients, one (1.6%) had HHV-6 infection
only, 41/63 (65.1%) — HHV-7 infection only, and 21/63
(33.3%) patients had concurrent HHV-6 and -7 infection.
Reactivation of HHV-6 was found in 16 (25.4%) and reacti-
vation of HHV-7 in 14 of 63 (22.2%) OA patients with per-
sistent HHV-6 and/or HHV-7 infection. In 7/21 (33.3%)
OA patients with persistent concurrent HHV-6 and HHV-7
infection, simultaneous reactivation of both viruses were
observed.
There were no OA patients with persistent HHV-6 mono-
infection at latent stage, but persistent HHV-7 infection at
latent stage was found in 34/41 (82.9%) and concurrent per-
sistent HHV-6 and HHV-7 infection at latent stage in 6/21
(28.6%) cases.
There were no OA patients with persistent HHV-6 mono-
infection at latent stage, but HHV-7 persistent infection at
latent stage was found in 34/41 (82.9%) and concurrent per-
sistent HHV-6 and HHV-7 infection at latent stage in 6/21
(28.6%) cases.
Healthy individuals. Persistent HHV-6 and/or persistent
HHV-7 infection was found in 15/19 (78.9%) healthy con-
trol group individuals. Of these cases, single HHV-6 infec-
tion was not found in any, single HHV-7 infection in 10/15
(66.7%) and concurrent HHV-6 and/or HHV-7 infection in
5/15 (33.3%) individuals.
Reactivation of HHV-6 was observed in 4/15 (26.7%) and
reactivation of HHV-7 infection in 3/15 (20.0%) healthy
control group individuals. Simultaneous reactivation of both
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Fig. 4. Level of IL-10 in RA (A, C) and OA (B, D) patients with different B19V (A, B) and HHV-6 and HHV-7 (C, D) infection activity stages; bars repre-
sent geometric mean with geometric SD, gray dotted line connects medians with IQR (bold gray lines), *p < 0.05, **p < 0.01, ***p < 0.001.
viruses was found in 1/5 (20.0%) healthy individuals with
persistent concurrent HHV-6 and HHV-7 infection.
There were no control group subjects with persistent
HHV-6 mono-infection at latent stage, but persistent
HHV-7 infection at latent stage was found in 8/10 (80.0%)
healthy control group individuals. Persistent infection of
both viruses (HHV-6 and HHV-7) at latent stage was found
in 1/5 (20.0%) healthy control group subjects.
Cytokine and MMP-9 levels of RA, OA patients and
healthy individuals with different activity phase of
HHV-6 and HHV-7 infections. RA patients. The mean
level of MMP-9 was considerably lower in RA patients
with active HHV-7 infection compared to RA patients with
latent HHV-7 infection (p < 0.0001), patients with active
HHV-6 infection (p = 0.01) and RA patients without
HHV-6 and HHV-7 infection (p < 0.0001, Fig. 1). The level
of TNF- was higher in RA patients with active HHV-7 in-
fection than in RA patients without HHV-6 and HHV-7 in-
fection (p < 0.05, Fig. 2). The mean level of IL-6 was con-
siderably lower in RA patients with active HHV-6 infection
than in patients without HHV-6 and HHV-7 infection (p <
0.05, Fig. 3). The mean level of IL-10 was significantly
lower in RA patients with active HHV-7 infection com-
pared to RA patients with latent HHV-7 infection (p <
0.01). However, the IL-10 level was higher in RA patients
without HHV-6 and HHV-7 infection than in patients with
active HHV-7 infection (p < 0.001), patients with active
HHV-6 infection (p < 0.05) and in patients with latent
HHV-6 infection (p < 0.05, Fig. 4).
OA patients. A higher mean MMP level was detected in OA
patients without HHV-6 and HHV7 infections compared to
OA patients with active HHV-7 infection (p < 0.05), with
latent HHV-7 infection (p < 0.05) and compared to OA pa-
tients with active HHV-6 infection (p < 0.01, Fig. 1). A
higher TNF- level was occurred in the OA patient group
with active HHV-6 infection than in patients without
HHV-6 and HHV-7 infection (p < 0.05, Fig. 2). The mean
level of IL-6 and IL-10 in OA patients at different activity
stages of persistent HHV-6 and HHV-7 infection did not
significantly differ.
Healthy individuals. No significant difference in MMP-9
and cytokine mean levels was found among healthy control
group individuals with different stages of B19V infection
activity.
DISCUSSION
Viruses and viral infections are an important risk factor for
the development of autoimmune diseases, especially in ge-
netically predisposed persons. Two-thirds of RA patients
have been observed to be positive for HLA-DR * 4 (Col-
megna and Alberts-Grill, 2009). The development of auto-
immune diseases, including connective tissue diseases, mul-
tiple sclerosis and Hashimoto thyroiditis, has been
associated with HHV-6 A/B infection (Chapenko et al.,
2003; Nora-Krukle et al., 2011; Caselli et al., 2012; Hayem
and Hayem, 2012; Broccolo et al., 2013, Sultanova et al.,
2017). It has been shown that several viral infections, in-
cluding B19V, HHV-6 and HHV-7, may trigger the devel-
opment and progression of arthritis. B19V-infection-in-
duced arthritis often meets RA criteria (Kerr, 2000;
Colmegna and Alberts-Grill, 2009; Khoqueer, 2009) and
prolonged B19V viremia may contribute to the develop-
ment of pronounced and prolonged arthritis (Ogawa et al.,
2008). B19V-induced arthritis is similar to RA progression
with symmetrical small joint damage (Kerr, 2000;
Takasawa et al., 2004; Franssil and Hedman, 2006).
Several studies are being conducted to reconfirm the re-
sponse of cells to B19V antigens and potential expression
of the B19V genome in patients (Takahashi et al., 1998;
Murai et al., 1999; Stahl et al.; 2000; Kozireva et al., 2008).
Although the B19V-specific immune response of cells is
being studied, there have been several studies on the devel-
opment of response in cases of acute and persistent B19V
infection. The role of persistent B19V infection in the de-
velopment of RA is shown by high incidence of B19V in-
fection among RA patients, lack of anti-B19 IgM class anti-
bodies in most RA patients with viremia and presence of
anti-B19 IgG class antibodies in these patients, frequent
finding of anti-B19 NS-1 IgG class antibodies in RA pa-
tients compared to healthy individuals, and relatively low
viral load in RA patients with viremia (von Poblotzki et al.,
1995; Hemauer et al., 2000; Kerr and Cunniffe, 2000; Lee
et al., 2011).
Some reports suggest that B19V infection also increases the
level of IL-6 (Tzang et al., 2009; Kerr, 2016;). Naciute and
colleagues (2016) showed association of IL-6 with higher
disease activity by the Disease Activity Score 28 (DAS28)
and C reactive protein (CRP). Our data also suggest that
B19V can alter the aggressiveness of RA and promote its
progression. The overall aggressiveness of the disease esti-
mated by the level of rheumatoid factor (RF) and anti-cyclic
citrullinated peptide (anti-CCP) has been shown to be
higher in RA patients with acute B19V infection than in pa-
tients without B19V infection and in patients with remote
B19V infection.
B19V promotes the production of various cytokines (Kerr et
al., 2004) and inflammatory cytokines and particularly
TNF- plays an important role in the development and pro-
gression of RA. In patients with acute and active persistent
B19V infection the level of TNF- is significantly higher
than in patients with remote B19V infection. In patients
with latent persistent B19V infection and active persistent
B19V infection, the level of TNF- is higher than in RA pa-
tients with acute B19V infection. Both Kerr (2001) and
Barash et al (2003) found that B19V infection at its acute
stage and subsequently may increase the level of TNF-,
thus promoting the development of RA after acute B19V in-
fection or reactivation of persistent B19V infection. The de-
tected MMP-9 level is significantly lower in RA patients
with active persistent B19V infection than in patients with
remote B19V infection, although Tzang et al. (2009) re-
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vealed an increase of MMP-9 activity under the influence of
B19-VP1u. Some reports suggest that B19V infection also
increases the level of IL-6 (Tzang et al., 2009; Kerr, 2016;
Naciute et al., 2016). Isa et al. (2007) observed that early
after acute B19V infection, the level of IL-12 increases,
then IL-2 increases, while IL-10 is low. In our study, the
mean level of IL-6 level was lower in RA patients with ac-
tive persistent B19V infection than in RA patients without
B19V infection, with remote B19V infection and in patients
with acute B19V infection. The different results may be ex-
plained by the treatment received in distinct patient groups.
The IL-12 level does not significantly differ in patients with
different activity stages of B19V infection.
B19V is able to influence the synthesis of cytokines: it has
been shown that the non-structural NS-1 protein of B19V
activates the expression of pro-inflammatory cytokines
(IL-6 and TNF-) in cells (Moffatt et al., 1996; Fu et al.,
2002; Hsu et al., 2006) and the recombinant B19V VP-1u
protein increases the expression of IL-6 and IL-1 mRNA
in macrophages (Tzang et al., 2009). It is possible that the
properties of this B19V in genetically predisposed individu-
als in the case of persistent B19V infection affect the devel-
opment of RA.
In OA patients, a considerably higher mean level of MMP-9
was found in the groups without B19V infection and with
remote B19V infection. A higher TNF- level occurred in
OA patients with active persistent B19V infection compared
to OA patients with latent persistent B19V infection, remote
B19V infection and without B19V infection, and a higher
level also occurred in OA patients with acute B19V infec-
tion compared to OA patients with remote B19V infection.
The level of IL-6 was lower in OA patients with acute
B19V infection than in patients without B19V infection.
Aslan et al. (2008) observed a higher IL-6 level in OA pa-
tients, depending on the degree of OA damage in the joint.
Our results would likely have differed if we evaluated OA
patients according to OA structural damages. The IL-10
level did not significantly differ in groups of OA patients
depending on the activity stage of B19V infection. The data
showed that active persistent and acute B19V infection are
associated with higher TNF- level and B19V levels, but
not with production of cytokines in the OA patients. No sig-
nificant difference in MMP-9 and cytokine levels was found
among healthy control group individuals with different
stages of B19V infection determined according to the
recomWell test.
B19V may alter plasma cytokine levels in RA patients and
healthy subjects (Naciute et al., 2016; Naciute et al., 2017).
In our study no significant differences in MMP-9, IL-6,
IL-10, and TNF- level were found between healthy control
group individuals with remote B19V infection and RA pa-
tients with remote B19V infection. Furthermore, a higher
IL-10 level occurred in the group of RA patients with re-
mote B19V infection than in the group of healthy individu-
als with remote B19V infection. This indicated that factors
other than B19V infection can affect the IL-10 level.
No significant differences in cytokine levels were found be-
tween the OA patient group and healthy control group indi-
viduals with remote B19V infection, in both studied groups.
In RA patients, the presence of HHV-6 genome and in-
creased viral loads can be statistically significantly higher
than in healthy controls (Alvarez-Lafuente et al., 2005).
Broccoli et al. (2013) also found that HHV-6 genomic se-
quences from cell-free serum (viremic) and anti-HHV-6
IgG antibodies were significantly more common in connec-
tive tissue diseases, including RA, compared to healthy con-
trol subjects. We did no observe significant differences in
reactivation of persistent HHV-6 and HHV-7 infection, as
well as reactivation of HHV-6 and HHV-7 in groups of RA
and OA patients, and healthy individuals. In the chronic in-
flammation process, lymphocytes containing HHV-6 and
HHV-7 genome sequences are found in the joint, which
suggest their potential role in the development of the dis-
ease.
The mean level of IL-6 was significantly lower in RA pa-
tients with active HHV-6 infection than in patients without
HHV-6 infection. The mean level of TNF- was higher in
RA patients group with active HHV-7 infection than in pa-
tients without HHV-6 and HHV-7 infection, but active and
latent HHV-6 infection and active HHV-7 infection down
regulate IL-10. The mean level of MMP-9 was considerably
lower in RA patients with active HHV-7 infection com-
pared to RA patients with latent HHV-7 infection, with ac-
tive HHV-6 infection and without HHV-6 and HHV-7 in-
fection. The data indicate that also latent infection, not only
active infection, can affect the course of RA. It was shown
previously that HHV-6 increased the production of inflam-
matory cytokines like IFN-, TNF-, IL-1, IL-8 and IL-15
and down regulated IL-2 and IL-10 (Lusso, 2006). This is in
line with our research data.
Among the cytokines and MMP-9 in OA patients at differ-
ent activity stages of persistent HHV-6 and HHV-7 infec-
tion, only the TNF- level was higher in patients with ac-
tive HHV-6 infection than in patients without HHV-6 and
HHV-7 infection, while the MMP-9 level is higher in pa-
tients without HHV-6 and HHV-7 infection than in patients
with active HHV-6 or HHV-7 and latent HHV-7 infection.
The data indicate a negligible role of these viruses in the
course of OA.
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CITOKÎNU UN MMP-9 LÎMENIS REIMATOÎDÂ ARTRÎTA UN OSTEOARTRÎTA PACIENTIEM AR PERSISTENTU
PARVOVÎRUSA B19, HHV-6 UN HHV-7 INFEKCIJU
Reimatoîdais artrîts (RA) ir hroniska autoimûna slimîba, kas izraisa erozîvas izmaiòas un ankilozi locîtavâs un var izraisît arî iekðçjo orgânu
bojâjumus. Osteoartrîts (OA) ir locîtavu skrimðïa deìeneratîvs process, taèu iekaisuma mediatoriem var bût bûtiska loma OA procesa
uzsâkðanâ un uzturçðanâ. Neraugoties uz daudziem ilgtermiòa pçtîjumiem, precîzs ðo slimîbas izraisîtâjs nav zinâms, tâpçc ir jâturpina pçtît
iespçjamie faktori, kas var veicinât ðo slimîbu attîstîbu. Ðî pçtîjuma mçríis bija novçrtçt parvovîrusa B19 (B19V) un, persistentas cilvçka
herpes vîrusa (HHV)-6 un HHV-7 infekcijas sastopamîbu un aktivitâtes stadiju RA un OA pacientiem, kâ arî veseliem cilvçkiem, un
analizçt citokînu un metalloproteinâzes (MMP)-9 lîmeòa izmaiòas atkarîbâ no vîrusa klâtbûtnes vai neesamîbas. RA pacientiem ar aktîvu
B19V infekciju ir visaugstâkais tumora nekrozes faktora alfa (TNF-) lîmenis, kas var veicinât RA attîstîbu. OA gadîjumâ TNF- lîmenis ir
augstâks pacientiem ar aktîvu persistentu B19V infekciju, un tas liecina, ka B19V reaktivâcija ietekmç arî OA attîstîbu un klînisko gaitu.
IL-6, IL-10 un MMP-9 lîmenis augstâks ir RA pacientiem ar latentu HHV-6/-7 infekciju, salîdzinot ar aktîvu HHV-6/-7 infekciju, bet OA
pacientiem visu noteikto citokînu lîmenis bûtiski neatðíiras. Tas liecina, ka arî latenta HHV-6 un -7 vîrusu infekcija var veicinât RA
attîstîbu.
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